Sarepta Confident Of Full US Approval For Duchenne Gene Therapy By Mid-2024

Elevidys has enjoyed a strong launch, despite being restricted to a small number of Duchenne patients. Sarepta is hoping the US regulator will overlook trial problems and allow its expanded use.